ELTROMBOPAG TEVA 50mg film-coated tablets medication leaflet

B02BX05 eltrombopag • Blood and blood forming organs | Vitamin k and other hemostatics | Other systemic hemostatics

Eltrombopag is a medication used to treat thrombocytopenia, a condition characterized by a low platelet count in the blood. It is particularly indicated for patients with chronic idiopathic thrombocytopenic purpura or other conditions affecting platelet production.

This medication works by stimulating thrombopoietin receptors in the bone marrow, leading to increased platelet production. It is taken orally, usually once daily, as directed by a doctor.

Eltrombopag is generally well-tolerated but may cause side effects such as nausea, fatigue, headaches, or elevated liver enzymes. In rare cases, there may be an increased risk of blood clots.

It is important to strictly follow your doctor's recommendations and undergo regular blood tests to monitor the treatment's effects. Do not discontinue the medication without consulting a specialist.

General data about ELTROMBOPAG TEVA 50mg

Substance: eltrombopag

Date of last drug list: 01-05-2026

Commercial code: W71031002

Concentration: 50mg

Pharmaceutical form: film-coated tablets

Quantity: 28

Product type: generic

Price: 4963.78 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ACTAVIS LTD. - MALTA

Holder: TEVA PHARMACEUTICALS S.R.L. - ROMANIA

Number: 15951/2025/02

Shelf life: 2 years

Concentrations available for eltrombopag

12.5mg, 25mg, 50mg, 75mg

Compensation lists for ELTROMBOPAG TEVA 50mg Teva

NHP 6.17 (C2) - Chronic immune thrombocytopenic purpura in splenectomized / non-splenectomized adults

Price

Copayment

Patient

4963.78 RON

2286.56 RON

2677.22 RON